Improving Medication Management in World Trade Center Responders
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Jun 8, 2025
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on helping World Trade Center (WTC) responders manage their medications better as they age. Many responders, especially those aged 50 and older, are taking multiple medications, which can lead to complications. The study aims to educate these individuals about their medications and encourage conversations with their doctors to safely reduce the number of unnecessary drugs they may be taking.
To participate in the trial, you need to be a WTC responder who is already part of a related study, be at least 50 years old, and currently taking specific types of medications, such as certain heartburn medications, sleep aids, or muscle relaxants. There are no exclusions, so if you meet these criteria, you might be eligible to join. Participants can expect to receive support and guidance on how to manage their medications more effectively, which could lead to better health outcomes and an improved quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A WTC responder already enrolled in the "Promoting Healthy Aging Among WTC Responders: Frailty Trajectories and Intervention Strategies" study cohort
- • aged 50 years or older, and
- * taking one of the five medication classes:
- • proton pump inhibitors (PPIs),
- • benzodiazepine (BZs) and
- • non-benzodiazepine sedative hypnotics ("Z-drugs"),
- • first-generation antihistamines (FGA), and
- • skeletal muscle relaxants (SMR).
- Exclusion Criteria:
- • None
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Fred Ko, MD
Principal Investigator
Icahn School of Medicine at Mount Sinai
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported